Dr. Guo Liang Yu is a co-founder, Executive Director, Chairman and Chief Executive Officer of Apollomics. Dr. Yu has been one of the key management members of the Company and has been actively involved in its business, strategy and operational management since its establishment. He has over 31 years of experience in the pharmaceutical industry and academic research. He is a serial entrepreneur and has co-founded over ten startup companies in biotech and the healthcare sectors, including Immune-Onc Therapeutics, Inc. in Palo Alto, United States. During his co-founding of our Group, Dr. Yu was the executive chairman of Crown Bioscience International and he was also a venture partner with OrbiMed Asia Limited.

Dr. Yu obtained his Ph.D. degree in molecular biology from the University of California, Berkeley in the U.S. He has served important roles in numerous social organizations, including the founding president of the Chinese Biopharmaceutical Association USA. Inc. and as a board member of Ray Wu Memorial Fund. Dr. Yu is currently a member of the Board of Directors of the following companies: Jiangsu Qyuns Therapeutics Co., Ltd., Immune-Onc Therapeutics, Inc., Zhejiang Innoforce Pharmaceuticals Co., and Inmagene Biopharmaceuticals.

Dr. Dong Liu has been a Director since November 2020. Dr. Liu has more than 20 years of international and domestic investment experience, and he is currently serving as the chairman of Ping An Capital. Prior to that, Dr. Liu served as the senior vice president of Government of Singapore Investment Corporation. He also consecutively served as the consultant, a member of Young Professional Scheme, the economist, the investment officer, the senior investment officer, the chief investment officer, and the manager of the Beijing office of the Bureau of East Asian and Pacific, International Finance Corporation.

Dr. Liu obtained his Bachelor of Engineering degree in naval architecture and ocean engineering and a Master’s degree in engineering from Shanghai Jiao Tong University in China. He obtained his Ph.D. degree from Wharton School, University of Pennsylvania in the United States. Dr. Liu is currently a director for Shanghai Jahwa United Co., Ltd., a company listed on the Shanghai Stock Exchange (SSE: 600315); and Autohome Inc., a company listed on the New York Stock Exchange (NYSE: ATHM).

Dr. Sanjeev Redkar is a co-founder, Executive Director and President of Apollomics. Dr. Redkar is mainly responsible for establishing and overseeing the overall strategic planning, business development and management of the Company. He has over 26 years of scientific, managerial and executive experience in hematology and oncology drug discovery and development, especially for small-molecule drugs. Dr. Redkar previously served as a senior vice president for product development at Astex Pharmaceuticals, Inc. (NASDAQ: ASTX) and worked as the manager of process development and manufacturing, senior director of pharmaceutical development, vice president in charge of manufacturing and preclinical development successively at SuperGen, Inc. before its acquisition of Astex Therapeutics Limited.

Dr. Redkar received his Bachelor of Technology degree in chemical engineering from Indian Institute of Technology in India, and he holds a Master of Science degree in chemical engineering and a Ph.D. degree in chemical engineering from University of Colorado, Boulder in the United States. He also obtained a Master of Business Administration degree from St. Mary’s College of California in the United States. Dr. Redkar has authored and co-authored over 25 peer-reviewed scientific articles and co-invented 26 patents that have been issued in the United States. Dr. Redkar serves as Adjunct Faculty and as an Industrial Advisory Board Member at the T.J. Long School of Pharmacy of the University of Pacific. He also serves as an External Advisory Board Member at the Department of Chemical and Biological Engineering of University of Colorado, Boulder.

Dr. Jonathan Wang has been a Director since July 2016. Dr. Wang has over 30 years of experience in the healthcare and life sciences industries, spanning entrepreneurship, investment, research and finance. He is currently the chairman and chief executive officer of Inmagene Biopharmaceuticals (Shanghai) Co., Ltd., and was previously a partner at OrbiMed Advisors LLC.

Dr. Wang obtained his Master of Arts, Master of Philosophy, and his Ph.D. from Columbia University in the United States. He also obtained an MBA degree from Stanford University in the United States. Dr. Wang has been a member of the Biotech Advisory Panel of the Hong Kong Stock Exchange since April 2018.

Dr. Steven Dasong Wang has been a Director since April 2020. Dr. Wang has over 20 years of experience in working in global investment banks and direct investment firms. He is a partner and senior management director of Asia at OrbiMed Advisors LLC, an investment fund with a focus on the healthcare industry.

Prior to joining OrbiMed, he served as a managing director and head of APAC Healthcare Investment Banking at Credit Suisse (Hong Kong) Limited. He also held senior level roles in the investment banking departments in Hong Kong of UBS AG and Morgan Stanley. Dr. Wang obtained his Bachelor of Arts degree in chemistry from the University of Southern Maine in the U.S. and his Ph.D. degree in medicinal chemistry from the Johns Hopkins University in the U.S.. He also holds a Master of Business Administration degree (with distinction) from New York University. Dr. Wang is a Chartered Financial Analyst with the Association for Investment Management and Research. He is also currently a member of the board of directors for Union Medical Healthcare Limited, a company listed on the Hong Kong Stock Exchange (stock code: 2138).

Dr. Kexiang Zhou has been a Director since December 2018. Dr. Zhou has over 20 years of industrial operational experience in the pharmaceutical industry. He is currently serving as a managing director at CMBI Capital Management (Shenzhen) Co., Ltd.

Dr. Zhou received his Bachelor of Science degree in medicine from Southern Medical University, formerly known as First Military Medical University. He received his M.D. and Ph.D. degrees from Peking University Health Science Center, formerly known as Beijing Medical College, in China.